11-dehydro-txb2

Introduction

To understand associated biological information of 11-dehydro-txb2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 11-dehydro-txb2?

11-dehydro-txb2 is suspected in Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 11-dehydro-txb2

MeSH term MeSH ID Detail
Diabetes Mellitus D003920 90 associated lipids
Inflammation D007249 119 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Asthma D001249 52 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Thrombosis D013927 49 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Brain Ischemia D002545 89 associated lipids
Per page 10 20 | Total 20

PubChem Associated disorders and diseases

What pathways are associated with 11-dehydro-txb2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

What functions are associated with 11-dehydro-txb2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

What genes are associated with 11-dehydro-txb2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with 11-dehydro-txb2

Download all related citations
Per page 10 20 50 100 | Total 283
Authors Title Published Journal PubMed Link
Dietrich-Muszalska A and Olas B Isoprostenes as indicators of oxidative stress in schizophrenia. 2009 World J. Biol. Psychiatry pmid:19673085
Hall JA et al. Dietary fish oil alters the lysophospholipid metabolomic profile and decreases urinary 11-dehydro thromboxane Bâ‚‚ concentration in healthy Beagles. 2011 Vet. Immunol. Immunopathol. pmid:21925741
Mullins KB et al. Effects of carprofen, meloxicam and deracoxib on platelet function in dogs. 2012 Vet Anaesth Analg pmid:22248445
Smith SR et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. 1993 Transplantation pmid:8279014
Takasaki W et al. Superiority of plasma 11-dehydro-TXB2 to TXB2 as an index of in vivo TX formation in rabbits after dosing of CS-518, a TX synthase inhibitor. 1993 Thromb. Res. pmid:8367836
Carroll RC et al. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. 2010 Thromb. Res. pmid:19962724
Kawamura M et al. Evaluation of plasma 11-dehydro-thromboxane B2 as an indicator for thromboxane A2 synthesis in vivo in laboratory animals. 1995 Thromb. Res. pmid:7778061
Cholette JM et al. Aspirin resistance following pediatric cardiac surgery. 2010 Thromb. Res. pmid:20550971
Perneby C et al. Prothrombotic responses to exercise are little influenced by clopidogrel treatment. 2004 Thromb. Res. pmid:15381386
Chakroun T et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. 2007 Thromb. Res. pmid:17553552
Kudolo GB et al. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. 2002 Thromb. Res. pmid:12590952
Di Minno MN et al. Genotype-independent in vivo oxidative stress following a methionine loading test: maximal platelet activation in subjects with early-onset thrombosis. 2011 Thromb. Res. pmid:21669453
Saloheimo P et al. Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. 2005 Thromb. Res. pmid:15733969
Pirich C et al. Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. 1999 Thromb. Res. pmid:10588465
Perneby C et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. 1999 Thromb. Res. pmid:10632465
Antonino MJ et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 2010 Thromb. Res. pmid:19446864
Santilli F et al. Effects of high-amount-high-intensity exercise on in vivo platelet activation: modulation by lipid peroxidation and AGE/RAGE axis. 2013 Thromb. Haemost. pmid:24030807
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Dragani A et al. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism. 2012 Thromb. Haemost. pmid:22782530
Lessiani G et al. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. 2011 Thromb. Haemost. pmid:21103664
Halawani SH et al. Aspirin failure in patients presenting with acute cerebrovascular ischaemia. 2011 Thromb. Haemost. pmid:21544317
Véricel E et al. Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients. 2015 Thromb. Haemost. pmid:25832443
Blais N et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). 2009 Thromb. Haemost. pmid:19652893
Koudstaal PJ et al. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. 1993 Stroke pmid:8421822
Tohgi H et al. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. 1992 Stroke pmid:1412574
Bruno A et al. Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients. 2002 Stroke pmid:11779889
Bruno A et al. Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. 2004 Stroke pmid:14963281
van Kooten F et al. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. 1999 Stroke pmid:10066850
van Kooten F et al. Evidence for episodic platelet activation in acute ischemic stroke. 1994 Stroke pmid:8303731
van Kooten F et al. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. 1997 Stroke pmid:9259748
van Kooten F et al. Increased thromboxane biosynthesis is associated with poststroke dementia. 1999 Stroke pmid:10436098
Gonzalez-Conejero R et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? 2005 Stroke pmid:15604423
Simeoni S et al. Stress-induced salivary cortisol secretion during hypobaric hypoxia challenge and in vivo urinary thromboxane production in healthy male subjects. 2011 Stress pmid:21434833
Haubelt H et al. Can platelet function tests predict the clinical efficacy of aspirin? 2005 Semin. Thromb. Hemost. pmid:16149017
Bruce EC et al. Platelet thromboxane A2 secretion in patients with major depression responsive to electroconvulsive therapy. 2008 Psychosom Med pmid:18378867
Suzuki N et al. Quantitative liquid chromatography-tandem mass spectrometric analysis of 11-dehydro TXB2 in urine. 2004 Prostaglandins Other Lipid Mediat. pmid:15165035
Mizugaki M et al. Monitoring of the thromboxane A2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method. 1999 Prostaglandins Other Lipid Mediat. pmid:10593167
Hishinuma T et al. Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic. 1999 Prostaglandins Other Lipid Mediat. pmid:10593168
Lynch CM et al. The role of thromboxane A(2) in the pathogenesis of intrauterine growth restriction associated with maternal smoking in pregnancy. 2011 Prostaglandins Other Lipid Mediat. pmid:21723954
Nishimaki S and Seki K An imbalance between prostacyclin and thromboxane in relation to cerebral blood flow in neonates with maternal preeclampsia. 1999 Prostaglandins Other Lipid Mediat. pmid:10482286
Suzuki N et al. Difference in urinary LTE4 and 11-dehydro-TXB2 excretion in asthmatic patients. 2000 Prostaglandins Other Lipid Mediat. pmid:11060902
Wolfram R et al. Daily prickly pear consumption improves platelet function. 2003 Prostaglandins Leukot. Essent. Fatty Acids pmid:12878452
Hishinuma T et al. Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications. 2001 Prostaglandins Leukot. Essent. Fatty Acids pmid:11728171
Sinzinger H Comments on "Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications". 2002 Prostaglandins Leukot. Essent. Fatty Acids pmid:12445490
Nakamura H et al. Difference in urinary 11-dehydro TXB2 and LTE4 excretion in patients with rheumatoid arthritis. 2001 Nov-Dec Prostaglandins Leukot. Essent. Fatty Acids pmid:11993724
Sciulli MG et al. Platelet activation in patients with colorectal cancer. 2005 Prostaglandins Leukot. Essent. Fatty Acids pmid:15626589
Tsuruta LR et al. Characterization of 11-dehydro-thromboxane B2 recombinant antibody obtained by phage display technology. 2003 Prostaglandins Leukot. Essent. Fatty Acids pmid:12628223
Lorenz R et al. A new method using simple solid phase extraction for the rapid gas-chromatographic mass-spectrometric determination of 11-dehydro-thromboxane B2 in urine. 1989 Prostaglandins pmid:2772221
Yamanaka S et al. 11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. 1993 Prostaglandins pmid:8484010
Schaefer WR et al. Urinary excretion of 2,3-dinor-6-keto-PGF1 alpha and 11-dehydro-TXB2 by the gravid spontaneously hypertensive rat. 1996 Prostaglandins pmid:8875634
Westlund P et al. Identification of 11-dehydro-TXB2 as a suitable parameter for monitoring thromboxane production in the human. 1986 Prostaglandins pmid:3755250
Kumlin M and Granström E Radioimmunoassay for 11-dehydro-TXB2: a method for monitoring thromboxane production in vivo. 1986 Prostaglandins pmid:3823488
Chiabrando C et al. Urinary excretion and origin of 11-dehydro-2,3-dinor-thromboxane B2 in man. 1993 Prostaglandins pmid:8321910
Seyberth HW et al. Excretion of primary prostanoids and their metabolites during acute volume expansion. 1988 Prostaglandins pmid:3163156
Farker K et al. Measurements of urinary prostaglandins in young ovulatory women during the menstrual cycle and in postmenopausal women. 1997 Prostaglandins pmid:9373880
Westlund P et al. Circulating and urinary thromboxane B2 metabolites in the rabbit: 11-dehydro-thromboxane B2 as parameter of thromboxane production. 1986 Prostaglandins pmid:3520685
Chiabrando C et al. Urinary excretion of 2,3-dinor-thromboxane B1, a major metabolite of thromboxane B2 in the rat. 1994 Prostaglandins pmid:7938613
d'Emmanuele di Villa Bianca R et al. Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. 2013 Proc. Natl. Acad. Sci. U.S.A. pmid:24019484
McAdam BF et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:9874808
Catella F et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. 1986 Proc. Natl. Acad. Sci. U.S.A. pmid:3461463
Montine TJ et al. Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. 2010 PLoS ONE pmid:20174466
Gremmel T et al. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. 2011 Platelets pmid:21231857
Hart RG et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease. 2003 Pharmacotherapy pmid:12741431
Saareks V et al. Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man. 2002 Pharmacol. Toxicol. pmid:12403056
Patrignani P et al. Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. 2008 Pharmacogenet. Genomics pmid:18551041
Heistein LC et al. Aspirin resistance in children with heart disease at risk for thromboembolism: prevalence and possible mechanisms. 2008 Pediatr Cardiol pmid:17896127
DeFilippis AP et al. Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity. 2014 Nutr Metab Cardiovasc Dis pmid:24370448
Mizugaki M [Microdetermination of eicosanoids using mass spectrometry]. 2000 Nippon Yakurigaku Zasshi pmid:10876809
Frost-Pineda K et al. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. 2011 Nicotine Tob. Res. pmid:21330277
McConnell JP et al. Urinary 11-dehydro-thromboxane B(2) and coagulation activation markers measured within 24 h of human acute ischemic stroke. 2001 Neurosci. Lett. pmid:11684346
Ciabattoni G et al. Determinants of platelet activation in Alzheimer's disease. 2007 Neurobiol. Aging pmid:16442186
Davì G et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. 1990 N. Engl. J. Med. pmid:2345567
Fitzgerald DJ et al. Platelet activation in unstable coronary disease. 1986 N. Engl. J. Med. pmid:3531859
Alessandrini P et al. Thromboxane biosynthesis and platelet function in type I diabetes mellitus. 1988 N. Engl. J. Med. pmid:3292913
Christman BW et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. 1992 N. Engl. J. Med. pmid:1603138
Geske FJ et al. AspirinWorks: a new immunologic diagnostic test for monitoring aspirin effect. 2008 Mol Diagn Ther pmid:18288882
Ciabattoni G et al. Radioimmunoassay of 11-dehydrothromboxane B2. 1990 Meth. Enzymol. pmid:2233352
Fitzgerald DJ et al. Thromboxane A2 synthesis in pregnancy-induced hypertension. 1990 Lancet pmid:1969511
Urinary thromboxane metabolites in pre-eclampsia. 1990 Lancet pmid:1971907
Van Geet C et al. Possible platelet contribution to pathogenesis of transient neonatal hyperammonaemia syndrome. 1991 Lancet pmid:1670726
Malini PL et al. Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. 1997 Lancet pmid:9217714
Tönshoff B et al. Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome. 1990 Kidney Int. pmid:2111418
Kapłon-Cieślicka A et al. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. 2013 Kardiol Pol pmid:24065375
Davì G et al. Platelet activation in obese women: role of inflammation and oxidant stress. 2002 Oct 23-30 JAMA pmid:12387653
Mills JL et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. 1999 JAMA pmid:10432033
Fritsma GA et al. Monitoring the antiplatelet action of aspirin. 2001 JAAPA pmid:11523339
Thomason J et al. Platelet cyclooxygenase expression in normal dogs. 2011 Sep-Oct J. Vet. Intern. Med. pmid:21985141
Dudley A et al. Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin. 2013 Jan-Feb J. Vet. Intern. Med. pmid:23278865
Lin JS et al. The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence. 1992 J. Urol. pmid:1635125
Hartanto MD et al. Urinary 11-dehydro-thromboxane B₂ and 2,3-dinor-6-keto-prostaglandin-F₁α in healthy post-menopausal and pre-menopausal women receiving aspirin 100 mg. 2012 J. Thromb. Thrombolysis pmid:22311294
Addad F et al. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. 2010 J. Thromb. Thrombolysis pmid:19381450
Olson MT et al. Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. 2012 J. Thromb. Haemost. pmid:23072449
Ferroni P et al. Platelet activation in type 2 diabetes mellitus. 2004 J. Thromb. Haemost. pmid:15304032
Ohmori T et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. 2006 J. Thromb. Haemost. pmid:16706971
De Cristofaro R et al. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 2003 J. Thromb. Haemost. pmid:12871497
Li C et al. Reversal of the anti-platelet effects of aspirin and clopidogrel. 2012 J. Thromb. Haemost. pmid:22268852
Lemkes BA et al. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. 2012 J. Thromb. Haemost. pmid:22252020
Santilli F et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 2010 J. Thromb. Haemost. pmid:20088941
Maga P et al. 11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period. 2016 J. Physiol. Pharmacol. pmid:27511998
Cullen L et al. Selective cyclooxygenase-2 inhibition by nimesulide in man. 1998 J. Pharmacol. Exp. Ther. pmid:9808683